Integration of DNA and RNA investigations in clinical trials: A laboratory chall...
Brandon Young - Bowden WIN Precision Oncology Laboratory, Murrieta, USA
Integration of DNA and RNA investigations in clinical trials: A laboratory challenge ( Brandon Young - Bowden WIN Precision Oncology Laboratory, Murrieta, USA )
10 Jul 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )
24 Jun 2019
The potential of PARP inhibitors in new cancer groups and in combination with ot...
Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston,...
The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2019
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions
Dr Joel Neal - Stanford University, Stanford, USA
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )
18 Jun 2019
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSC...
Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spai...
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
11 Jun 2019
Pembrolizumab increases long-term survival in patients with advanced NSCLC
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA
Pembrolizumab increases long-term survival in patients with advanced NSCLC ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )
11 Jun 2019
Expanding clinical trial eligibility criteria: Risks and solutions
Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA
Expanding clinical trial eligibility criteria: Risks and solutions ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )
11 Jun 2019
Carfilzomib and irinotecan in relapsed small cell lung cancer
Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA
Carfilzomib and irinotecan in relapsed small cell lung cancer ( Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA )
6 Jun 2019
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients wit...
Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA
Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC ( Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA )
6 Jun 2019
Understanding eligibility criteria for clinical trials to increase study size
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills,...
Understanding eligibility criteria for clinical trials to increase study size ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )
3 Jun 2019
Expanded clinical trial inclusion criteria would double the percentage of patien...
Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills,...
Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )
3 Jun 2019
Clinical and translational results from the NEOSTAR study: Treating early-stage ...
Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, US...
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2019